<p>Prestige Consumer Healthcare Inc.（纽约证券交易所代码：PBH - 免费报告）- Zacks Research 在 12 月 23 日（星期二）发布的报告中上调了 Prestige Consumer Healthcare 2027 年第一季度每股收益的预期。Zacks Research 分析师团队现在预测该公司本季度每股收益为 1.24 美元，高于之前预测的 1.23 美元。Zacks Research 目前对该股票的评级为 “持有”。Prestige Consumer Healthcare 当前全年的每股收益共识预期为 4.50 美元。</p>
<p>Prestige Consumer Healthcare（纽约证券交易所代码：PBH - 获取免费报告）最近于 11 月 6 日（星期四）公布了季度财报。该公司报告本季度每股收益为 1.07 美元，超出市场共识预期的 0.97 美元，超出幅度为 0.10 美元。该业务本季度的收入为 2.7411 亿美元，而分析师预期为 2.5714 亿美元。Prestige Consumer Healthcare 的净利润率为 18.09%，股本回报率为 12.43%。与去年同期相比，该公司的季度收入下降了 3.4%。去年同期，该公司每股收益为 1.09 美元。Prestige Consumer Healthcare 已将 2026 财年的指导目标设定为每股收益 4.540-4.580 美元。</p>
<p>其他几位股票分析师最近也对 PBH 发表了看法。Jefferies Financial Group 在 10 月 27 日（星期一）的研究报告中将 Prestige Consumer Healthcare 的目标价从 75.00 美元下调至 71.00 美元，并对该股票给予 “持有” 评级。Canaccord Genuity Group 在 11 月 7 日（星期五）的研究报告中将 Prestige Consumer Healthcare 的目标价从 100.00 美元下调至 88.00 美元，并给予 “买入” 评级。Oppenheimer 在 10 月 21 日（星期二）的研究报告中将 Prestige Consumer Healthcare 的目标价从 82.00 美元下调至 72.00 美元，并给予 “跑赢大盘” 评级。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重新发布了对 Prestige Consumer Healthcare 的 “持有（c）” 评级。最后，Sidoti 在 9 月 24 日（星期三）的研究报告中将 Prestige Consumer Healthcare 的评级从 “中性” 上调至 “买入”，并设定了 80.00 美元的目标价。四位分析师对该股票给予 “买入” 评级，四位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，平均目标价为 85.33 美元。</p>
<p><strong>获取我们关于 PBH 的最新报告</strong></p>
<h2>Prestige Consumer Healthcare 股票上涨 0.2%</h2>
<p>NYSE:PBH 的股票在星期四以 62.42 美元开盘。该公司的 50 日移动平均线为 60.76 美元，200 日移动平均线为 67.61 美元。Prestige Consumer Healthcare 的 12 个月低点为 57.25 美元，12 个月高点为 90.04 美元。该股票的市值为 30 亿美元，市盈率为 15.49，PEG 比率为 1.96，贝塔值为 0.39。该公司的速动比率为 2.51，流动比率为 3.70，债务与股本比率为 0.55。</p>
<h2>Prestige Consumer Healthcare 的机构交易</h2>
<p>几家对冲基金最近对该公司的持仓进行了调整。Price T Rowe Associates Inc. MD 在第一季度将其在 Prestige Consumer Healthcare 的股份增加了 2.4%。Price T Rowe Associates Inc. MD 目前拥有 466,204 股该公司的股票，价值 40,081,000 美元，在此期间又增持了 11,112 股。Jane Street Group LLC 在第一季度将其在 Prestige Consumer Healthcare 的持仓增加了 204.0%。Jane Street Group LLC 目前拥有 104,802 股该公司的股票，价值 9,010,000 美元，在此期间又购买了 70,330 股。Rafferty Asset Management LLC 在第一季度将其在 Prestige Consumer Healthcare 的持仓增加了 16.0%。Rafferty Asset Management LLC 目前拥有 3,711 股该公司的股票，价值 319,000 美元，在此期间又购买了 513 股。OMERS ADMINISTRATION Corp 在第一季度购买了 Prestige Consumer Healthcare 的新股份，价值约 997,000 美元。最后，Magnetar Financial LLC 在第一季度购买了 Prestige Consumer Healthcare 的新股份，价值约 1,433,000 美元。目前 99.95% 的股票由机构投资者持有。</p>
<h2>Prestige Consumer Healthcare 的内部活动</h2>
<p>在相关消息中，副总裁 Jeffrey Zerillo 于 11 月 28 日（星期五）出售了 719 股该公司的股票。该股票以平均价格 60.00 美元出售，总价值为 43,140.00 美元。交易后，该副总裁在公司中持有 42,329 股，价值约 2,539,740 美元。这代表其持股比例减少了 1.67%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。公司内部人士持有该公司 1.40% 的股票。</p>
<h2>关于 Prestige Consumer Healthcare</h2>
<p>（获取免费报告）</p>
<p>Prestige Consumer Healthcare, Inc 是一家领先的品牌非处方（OTC）医疗产品制造商和营销商。该公司专注于开发、收购和商业化多样化的非处方药物组合，旨在满足消费者的常见健康需求，包括疼痛缓解、感冒和咳嗽、消化健康、眼部护理、皮肤护理和女性健康。</p>
<p>Prestige 的主要品牌包括 Clear Eyes（眼部健康）、Carmex（唇部护理）、Chloraseptic（喉咙痛缓解）、Dramamine（晕动病）、Rolaids（抗酸药）、Monistat（女性健康）、BC Powder（疼痛缓解）、Little Remedies（儿童感冒和气体缓解）和 TheraTears（干眼治疗）。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Prestige Consumer Healthcare</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “3 美元 AI 奇迹股” 即将爆发</li>
<li>是否可以从资本利得税中扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘记 AI，这将是下一个重大科技突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Prestige Consumer Healthcare 吗？</h2>
<p>在考虑 Prestige Consumer Healthcare 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Prestige Consumer Healthcare 并不在名单上。</p>
<p>虽然 Prestige Consumer Healthcare 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

普雷斯蒂奇

<p>Zacks Research 已将对 Prestige Consumer Healthcare 2027 年第一季度每股收益的预期上调至 1.24 美元，较之前的 1.23 美元有所增加。该公司的评级为 “持有”，全年每股收益的共识预期为 4.50 美元。分析师的评级意见不一，整体共识为 “适度买入”，平均目标价为 85.33 美元。该股票目前的交易价格为 62.42 美元，市值为 30 亿美元</p>

<p>Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Zacks Research raised their Q1 2027 EPS estimates for Prestige Consumer Healthcare in a report released on Tuesday, December 23rd. Zacks Research analyst Team now forecasts that the company will post earnings of $1.24 per share for the quarter, up from their previous forecast of $1.23. Zacks Research currently has a &#34;Hold&#34; rating on the stock. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.50 per share.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare Inc.（纽约证券交易所代码：PBH - 免费报告）- Zacks Research 在 12 月 23 日（星期二）发布的报告中上调了 Prestige Consumer Healthcare 2027 年第一季度每股收益的预期。Zacks Research 分析师团队现在预测该公司本季度每股收益为 1.24 美元，高于之前预测的 1.23 美元。Zacks Research 目前对该股票的评级为 “持有”。Prestige Consumer Healthcare 当前全年的每股收益共识预期为 4.50 美元。</p>
</div><p>Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported $1.07 earnings per share for the quarter, beating the consensus estimate of $0.97 by $0.10. The business had revenue of $274.11 million for the quarter, compared to analysts' expectations of $257.14 million. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The firm's revenue for the quarter was down 3.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.09 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare（纽约证券交易所代码：PBH - 获取免费报告）最近于 11 月 6 日（星期四）公布了季度财报。该公司报告本季度每股收益为 1.07 美元，超出市场共识预期的 0.97 美元，超出幅度为 0.10 美元。该业务本季度的收入为 2.7411 亿美元，而分析师预期为 2.5714 亿美元。Prestige Consumer Healthcare 的净利润率为 18.09%，股本回报率为 12.43%。与去年同期相比，该公司的季度收入下降了 3.4%。去年同期，该公司每股收益为 1.09 美元。Prestige Consumer Healthcare 已将 2026 财年的指导目标设定为每股收益 4.540-4.580 美元。</p>
</div><p>Several other equities analysts have also recently weighed in on PBH. Jefferies Financial Group dropped their price objective on Prestige Consumer Healthcare from $75.00 to $71.00 and set a &#34;hold&#34; rating on the stock in a research note on Monday, October 27th. Canaccord Genuity Group dropped their price target on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, November 7th. Oppenheimer reduced their price objective on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an &#34;outperform&#34; rating for the company in a research report on Tuesday, October 21st. Weiss Ratings reissued a &#34;hold (c)&#34; rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, October 8th. Finally, Sidoti upgraded Prestige Consumer Healthcare from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $80.00 target price on the stock in a research note on Wednesday, September 24th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $85.33.</p>
<div class="lb-trans"><p>其他几位股票分析师最近也对 PBH 发表了看法。Jefferies Financial Group 在 10 月 27 日（星期一）的研究报告中将 Prestige Consumer Healthcare 的目标价从 75.00 美元下调至 71.00 美元，并对该股票给予 “持有” 评级。Canaccord Genuity Group 在 11 月 7 日（星期五）的研究报告中将 Prestige Consumer Healthcare 的目标价从 100.00 美元下调至 88.00 美元，并给予 “买入” 评级。Oppenheimer 在 10 月 21 日（星期二）的研究报告中将 Prestige Consumer Healthcare 的目标价从 82.00 美元下调至 72.00 美元，并给予 “跑赢大盘” 评级。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重新发布了对 Prestige Consumer Healthcare 的 “持有（c）” 评级。最后，Sidoti 在 9 月 24 日（星期三）的研究报告中将 Prestige Consumer Healthcare 的评级从 “中性” 上调至 “买入”，并设定了 80.00 美元的目标价。四位分析师对该股票给予 “买入” 评级，四位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，平均目标价为 85.33 美元。</p>
</div><p><strong>Get Our Latest Report on PBH</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 PBH 的最新报告</strong></p>
</div><h2>Prestige Consumer Healthcare Stock Up 0.2%</h2>
<div class="lb-trans"><h2>Prestige Consumer Healthcare 股票上涨 0.2%</h2>
</div><p>Shares of NYSE:PBH opened at $62.42 on Thursday. The business's 50 day moving average is $60.76 and its 200 day moving average is $67.61. Prestige Consumer Healthcare has a 12-month low of $57.25 and a 12-month high of $90.04. The stock has a market cap of $3.00 billion, a price-to-earnings ratio of 15.49, a PEG ratio of 1.96 and a beta of 0.39. The company has a quick ratio of 2.51, a current ratio of 3.70 and a debt-to-equity ratio of 0.55.</p>
<div class="lb-trans"><p>NYSE:PBH 的股票在星期四以 62.42 美元开盘。该公司的 50 日移动平均线为 60.76 美元，200 日移动平均线为 67.61 美元。Prestige Consumer Healthcare 的 12 个月低点为 57.25 美元，12 个月高点为 90.04 美元。该股票的市值为 30 亿美元，市盈率为 15.49，PEG 比率为 1.96，贝塔值为 0.39。该公司的速动比率为 2.51，流动比率为 3.70，债务与股本比率为 0.55。</p>
</div><h2>Institutional Trading of Prestige Consumer Healthcare</h2>
<div class="lb-trans"><h2>Prestige Consumer Healthcare 的机构交易</h2>
</div><p>Several hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its stake in shares of Prestige Consumer Healthcare by 2.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 466,204 shares of the company's stock worth $40,081,000 after acquiring an additional 11,112 shares during the period. Jane Street Group LLC boosted its position in Prestige Consumer Healthcare by 204.0% during the first quarter. Jane Street Group LLC now owns 104,802 shares of the company's stock worth $9,010,000 after purchasing an additional 70,330 shares during the period. Rafferty Asset Management LLC boosted its position in Prestige Consumer Healthcare by 16.0% during the first quarter. Rafferty Asset Management LLC now owns 3,711 shares of the company's stock worth $319,000 after purchasing an additional 513 shares during the period. OMERS ADMINISTRATION Corp purchased a new position in shares of Prestige Consumer Healthcare in the first quarter worth about $997,000. Finally, Magnetar Financial LLC bought a new stake in shares of Prestige Consumer Healthcare in the first quarter valued at approximately $1,433,000. 99.95% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金最近对该公司的持仓进行了调整。Price T Rowe Associates Inc. MD 在第一季度将其在 Prestige Consumer Healthcare 的股份增加了 2.4%。Price T Rowe Associates Inc. MD 目前拥有 466,204 股该公司的股票，价值 40,081,000 美元，在此期间又增持了 11,112 股。Jane Street Group LLC 在第一季度将其在 Prestige Consumer Healthcare 的持仓增加了 204.0%。Jane Street Group LLC 目前拥有 104,802 股该公司的股票，价值 9,010,000 美元，在此期间又购买了 70,330 股。Rafferty Asset Management LLC 在第一季度将其在 Prestige Consumer Healthcare 的持仓增加了 16.0%。Rafferty Asset Management LLC 目前拥有 3,711 股该公司的股票，价值 319,000 美元，在此期间又购买了 513 股。OMERS ADMINISTRATION Corp 在第一季度购买了 Prestige Consumer Healthcare 的新股份，价值约 997,000 美元。最后，Magnetar Financial LLC 在第一季度购买了 Prestige Consumer Healthcare 的新股份，价值约 1,433,000 美元。目前 99.95% 的股票由机构投资者持有。</p>
</div><h2>Insider Activity at Prestige Consumer Healthcare</h2>
<div class="lb-trans"><h2>Prestige Consumer Healthcare 的内部活动</h2>
</div><p>In related news, VP Jeffrey Zerillo sold 719 shares of the company's stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $60.00, for a total value of $43,140.00. Following the transaction, the vice president owned 42,329 shares in the company, valued at approximately $2,539,740. This represents a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Company insiders own 1.40% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，副总裁 Jeffrey Zerillo 于 11 月 28 日（星期五）出售了 719 股该公司的股票。该股票以平均价格 60.00 美元出售，总价值为 43,140.00 美元。交易后，该副总裁在公司中持有 42,329 股，价值约 2,539,740 美元。这代表其持股比例减少了 1.67%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。公司内部人士持有该公司 1.40% 的股票。</p>
</div><h2>About Prestige Consumer Healthcare</h2>
<div class="lb-trans"><h2>关于 Prestige Consumer Healthcare</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare, Inc 是一家领先的品牌非处方（OTC）医疗产品制造商和营销商。该公司专注于开发、收购和商业化多样化的非处方药物组合，旨在满足消费者的常见健康需求，包括疼痛缓解、感冒和咳嗽、消化健康、眼部护理、皮肤护理和女性健康。</p>
</div><p>Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).</p>
<div class="lb-trans"><p>Prestige 的主要品牌包括 Clear Eyes（眼部健康）、Carmex（唇部护理）、Chloraseptic（喉咙痛缓解）、Dramamine（晕动病）、Rolaids（抗酸药）、Monistat（女性健康）、BC Powder（疼痛缓解）、Little Remedies（儿童感冒和气体缓解）和 TheraTears（干眼治疗）。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Prestige Consumer Healthcare</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Prestige Consumer Healthcare</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “3 美元 AI 奇迹股” 即将爆发</li>
<li>是否可以从资本利得税中扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘记 AI，这将是下一个重大科技突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=PBH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Prestige Consumer Healthcare Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Prestige Consumer Healthcare 吗？</h2>
</div><p>Before you consider Prestige Consumer Healthcare, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Prestige Consumer Healthcare 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Prestige Consumer Healthcare 并不在名单上。</p>
</div><p>While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Prestige Consumer Healthcare 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Zacks 研究对 PBH 第一季度的收益预测持乐观态度